The RNAscope™ technology enables fast and rigorous target and biomarker development: it is a robust and ultra-sensitive RNA in situ hybridization (RNA ISH) method providing single-cell and single-molecule RNA detection in the context of complex tissue microenvironments. Advanced Cell Diagnostics’ Professional Assay Services is the only CRO specialized in providing RNAscope and BaseScope ISH.
In this webinar, we will introduce assay service offerings that combine analysis of any target by RNAscope in situ hybridization (ISH) with immune cell and checkpoint marker immunohistochemistry (IHC) and immunofluorescence (IF) assays. Our services provide spatial analysis of target antigens, biomarkers, cytokines, or CAR-T cells together with immune cell distribution within the tumor microenvironment (TME). All RNAscope probes can be multiplexed together with our validated IHC and IF assays. Please join us to hear how our services are contributing to and advancing the therapeutic development programs of hundreds of pharma and biotech companies worldwide.
- Use of ISH-IHC/IF assays to support preclinical immuno-oncology research and biomarker validation
- Surveillance of immune cell and check-point markers in the TME
- CAR-T and TCR T-cell tumor infiltration and activation in pre- vs post-treatment clinical biopsies
- Validated ISH/IHC protocols for co-detection of biomarkers and immune cell markers
- Quality-controlled tissue bank that includes solid tumors, normal human tissues, and TMAs available for target safety/ADME assessment or any other research needs
